PCV35 THE BUDGET IMPACT ANALYSIS OF AMBRISENTAN IN 2ND LINE TREATMENT OF ADULT PATIENTS WITH IDIOPATHIC, FAMILIAR OR ASSOCIATED WITH CONNECTIVE TISSUE DISEASE PULMONARY HYPERTENSION OF III NYHA STAGE
Nov 1, 2010, 00:00 AM
10.1016/S1098-3015(11)72378-6
https://www.valueinhealthjournal.com/article/S1098-3015(11)72378-6/fulltext
Section Title :
RESEARCH POSTER ABSTRACTS
Section Order :
537
First Page :
A347
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72378-6&doi=10.1016/S1098-3015(11)72378-6